Skip to main content

Table 1 Costs and resource use assumptions

From: Cost impact of a non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service setting

Variable

Individual scenario

Time-derived

Definition

Source

Administration costs Botox initial cycle

£513.60

£70.00

Spire: Treatment (£650 incl. follow-up visits and drug) + initial adminstration (£140) − drug costs/Time-based: Consultant visit lasts 30 min plus 15 min nurse time

http://www.spirehealthcare.com/hull/news/botox-for-migraine-treatment/. Accessed 14/02/2016, PSSRU, unit costs of health and social care 2014 (Curtis 2014)

Administration costs Botox every 12 weeks

£373.60

£60.00

Spire Hull: Treatment (£650, incl. follow-up visits and drug) - drug costs/Time-based: Consultant visit lasts 15 min plus 15 min nurse time

http://www.spirehealthcare.com/hull/news/botox-for-migraine-treatment/. Accessed 14/02/2016, PSSRU, unit costs of health and social care 2014 (Curtis 2014),

Botox drug costs per 12 weeks cycle

£276.40

£276.40

Drug costs

NICE Botox appraisal

Botox drug costs for 48 week cycle

£276.40

£276.40

Drug costs

NICE Botox appraisal

Administration costs TMS in initial quarter

£140.00

£35.00

Spire Hull: Initial consultation fee £140/Time-based: Consultant visit lasts 15 min

http://www.spirehealthcare.com/hull/news/botox-for-migraine-treatment/. Accessed 14/02/2016; PSSRU (Curtis 2014), Personal communication Hull

Administration costs TMS in follow-up quarter

0

0

Device used at home by patient

 

Costs TMS in initial quarter responder

0

0

Not applied due to risk share approach

Manufacturer

Costs TMS in follow-up quarter responder

£450.00

£450.00

Current sTMS costs

Manufacturer

Costs 1 GP Visit

£45.63

£45.63

Surgery consultation last 11.7 min £3.90 per min (with qualification costs) incl. direct staff (Table 10.8b)

PSSRU, unit costs of health and social care 2014 (Curtis 2014)

Costs hospital inpatient stay migraine

£514.00

£514.00

NHS 2013/14 National Tariff—Patients continuing on Botox and TMS were assumed to be in need for furhter neurologists visits; PA04B applied for dicontinuing

https://www.gov.uk/government/collections/payment-by-results-2013-14. Accessed 14/02/2016

Costs neurologist visit

£128.00

£128.00

National tariff information spreadsheet-index: Neurology and Neurosurgery outpatient attendances

https://www.gov.uk/government/collections/payment-by-results-2013-14. Accessed 14/02/2016

Costs emergency department visit

£78.00

£78.00

National Tariff—VB09Z

https://www.gov.uk/government/collections/payment-by-results-2013-14. Accessed 14/02/2016

Costs Triptan use per attack

£1.08

£1.08

Weighted average for the mean cost of 1 triptan tablet in NHS England 2014

http://www.hscic.gov.uk/catalogue/PUB17274/pres-cost-anal-eng-2014-rep.pdf and Botox appraisal 2011

Number of A&E events per quarter

0.51

0.51

UK specific data from IBMS, Table 3

Bloudek et al. (2012)

Number of GP visits for migraine per quarter

1.44

1.44

UK specific data from IBMS, Table 3

Bloudek et al. (2012) and Blumenfeld et al. (2011)

Number of hospital inpatient stays per quarter

0.09

0.09

UK specific data from IBMS, Table 3

Bloudek et al. (2012)

Number of neurologists visit per quarter

0.43

0.43

UK specific data from IBMS, Table 3

Bloudek et al. (2012)

Number of Triptans used per quarter

7.29

7.29

7.29 triptans used for patients more than 15 attacks

NICE Botox Appraisal (2011): Table 6.17 page 160

Probability Botox continuation

45.5 %

45.5 %

Responder after cycle 2 based on Khalil et al. (2015b)

Khalil et al. (2015b)

Probability TMS continuation

53.7 %

53.7 %

Discontinuer minus those discontinuing due to lack of funding

Bhola et al. (2015)

Botox resource use reduction per responder 12 weeks

49.7 %

49.7 %

Observed reduction rate in observational trial

Rothrock (2011), Table 3

TMS resource use reduction per responder quarter

46.7 %

46.7 %

Observed reduction rate in observational trial

Bhola et al. (2015), Table 3